Ascentage Pharma Announces Trustee Purchase of Shares for 2022 RSU Scheme on June 10, 2026

Ascentage Pharma Group International: Trustee Purchases Shares for 2022 RSU Scheme

Key Highlights

Trustee Acquires 190,000 Shares for 2022 RSU Scheme: On June 10, 2026, the trustee of Ascentage Pharma Group International purchased 190,000 existing shares on-market. The purpose of this acquisition is to satisfy the Restricted Share Units (RSUs) under the company’s 2022 RSU Scheme.
Total Consideration and Price Paid: The shares were acquired at a total consideration of approximately HK\$6,418,500, implying an average price of about HK\$33.78 per share (excluding related fees and levies).
Impact on Share Capital: The 190,000 purchased shares represent approximately 0.0509% of the total issued shares of the company as of the date of this announcement.
Accumulated Shares Held by Trustee: Immediately after this purchase, the trustee holds a total of 2,505,000 shares for the purpose of the 2022 RSU Scheme.
RSU Scheme Update: No additional RSU awards have been granted under the 2022 Scheme beyond the initial and subsequently disclosed grants.
Board Composition: The company board comprises prominent figures including Dr. Yang Dajun (Chairman and Executive Director), and several independent non-executive directors with international credentials.

Details for Investors

The purchase of shares by the trustee is a routine but significant event for shareholders, as it directly relates to the company’s approach to talent retention and alignment of management incentives via the RSU scheme. The 2022 RSU Scheme, with both initial and further grants, is designed to incentivize employees and directors, aligning their interests with those of shareholders.

It is important for investors to note that the shares purchased for the RSU Scheme are existing shares bought on the market, rather than new shares being issued. This avoids diluting the share capital, which can be considered a shareholder-friendly move. The trustee, as stipulated by the scheme rules and trust deed, will not exercise voting rights for these shares while they are held on trust.

Price-Sensitive Information & Potential Impact on Share Value

The company paid an average price of HK\$33.78 for the purchased shares, which may be interpreted by the market as a signal of management’s confidence in the company’s intrinsic value.
The share purchase for the RSU Scheme is unlikely to have an immediate, direct impact on share price due to its relatively small size (just 0.0509% of issued shares), but it demonstrates continued execution of the company’s employee incentive plans, which can have long-term positive effects on retention and performance.
No further RSU grants have been made beyond those already announced, so there are no new sources of potential dilution or significant changes in the incentive structure at this time.

Other Notable Information

The trustee now holds a cumulative total of 2,505,000 shares for the RSU scheme.
Board composition includes both executive leadership and a strong roster of independent directors, with compliance to both Hong Kong and U.S. governance standards.

Conclusion

While this announcement reflects normal course activity related to the management’s equity incentive program, the purchase price and volume may be of interest to investors tracking insider and trustee activity. However, there are no immediate red flags, nor does this event represent a material change to the company’s financial position or capital structure.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should perform their own due diligence and consult professional advisors before making investment decisions. The author and publisher assume no responsibility for actions taken based on the information provided herein.

亞盛醫藥集團國際：受託人為2022年RSU計劃增持股份

重點摘要

受託人增持190,000股股份： 於2026年6月10日，亞盛醫藥集團國際的受託人於市場上購買了190,000股現有股份，用於履行公司2022年RSU計劃下的受限制股份單位（RSU）。
總代價及購買價格： 今次購股總代價約為港幣6,418,500元，平均每股價格約為港幣33.78元（不包括相關費用及徵費）。
股份總發行比例： 今次購買股份佔公司總已發行股份約0.0509%。
受託人累計持股： 完成本次購買後，受託人共持有2,505,000股股份作為2022年RSU計劃用途。
RSU計劃最新情況： 除已公佈的初次及後續授予外，未有新RSU獎勵頒發。
董事會組成： 公司董事會成員包括楊大俊博士（主席及執行董事）、多位獨立非執行董事及國際專業人士。

投資者須知詳情

受託人本次增持股份屬於公司人才激勵計劃（RSU計劃）正常執行，有助於吸引和留住關鍵人才，將高層利益與股東利益一致化。特別要留意，所購股份為現有股份，並非新發行股份，因此不會攤薄現有股東權益，屬於友好舉措。根據信託契約及計劃規則，受託人持有股份期間不會行使投票權。

可能影響股價的重要事項

公司以每股港幣33.78元的均價購股，反映管理層對公司內在價值有信心，市場或會正面解讀。
購股規模佔比不大（僅約0.0509%），對即時股價影響有限，但長遠有助於激勵計劃順利推展，提升管理層積極性及公司表現。
目前未有新RSU授出，亦無額外潛在攤薄或激勵架構重大變動。

其他值得留意事項

受託人目前持有2,505,000股股份用於RSU計劃。
董事會成員結構多元，符合香港及美國企業管治要求。

總結

是次公告屬例行激勵計劃操作，受託人購股價格及數量可供關注內部動態的投資者參考。整體而言，事件對公司財務狀況及資本架構並無重大影響，亦無即時紅色警號。

免責聲明： 本文僅供參考，並不構成任何投資建議。投資者應自行審慎分析，或諮詢專業人士後作出投資決定。作者及發佈方對因資料而引致的任何決定或行動不承擔責任。